AP2012006064A0 - Compounds and methods for treating influenza. - Google Patents

Compounds and methods for treating influenza.

Info

Publication number
AP2012006064A0
AP2012006064A0 AP2012006064A AP2012006064A AP2012006064A0 AP 2012006064 A0 AP2012006064 A0 AP 2012006064A0 AP 2012006064 A AP2012006064 A AP 2012006064A AP 2012006064 A AP2012006064 A AP 2012006064A AP 2012006064 A0 AP2012006064 A0 AP 2012006064A0
Authority
AP
ARIPO
Prior art keywords
compounds
methods
treating influenza
influenza
treating
Prior art date
Application number
AP2012006064A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Edward J Semple
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43381033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2012006064(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of AP2012006064A0 publication Critical patent/AP2012006064A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
    • H01L31/12—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof structurally associated with, e.g. formed in or on a common substrate with, one or more electric light sources, e.g. electroluminescent light sources, and electrically or optically coupled thereto
    • H01L31/125—Composite devices with photosensitive elements and electroluminescent elements within one single body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Power Engineering (AREA)
  • Electromagnetism (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AP2012006064A 2009-06-26 2010-06-23 Compounds and methods for treating influenza. AP2012006064A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22089109P 2009-06-26 2009-06-26
PCT/US2010/039638 WO2010151577A1 (en) 2009-06-26 2010-06-23 Compounds and methods for treating influenza

Publications (1)

Publication Number Publication Date
AP2012006064A0 true AP2012006064A0 (en) 2012-02-29

Family

ID=43381033

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006064A AP2012006064A0 (en) 2009-06-26 2010-06-23 Compounds and methods for treating influenza.

Country Status (16)

Country Link
US (6) US9023877B2 (xx)
EP (2) EP3895706A1 (xx)
JP (3) JP5932640B2 (xx)
KR (4) KR20180032689A (xx)
CN (2) CN108042535A (xx)
AP (1) AP2012006064A0 (xx)
AU (2) AU2010264479B2 (xx)
BR (2) BRPI1014322A2 (xx)
CA (3) CA3038405C (xx)
EA (1) EA030679B1 (xx)
ES (1) ES2914949T3 (xx)
HK (1) HK1255283A1 (xx)
MX (1) MX341877B (xx)
PT (1) PT2445349T (xx)
WO (1) WO2010151577A1 (xx)
ZA (1) ZA201200263B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5918124B2 (ja) 2009-05-12 2016-05-18 ロマーク ラボラトリーズ エル．シー． ハロアルキルヘテロアリールベンズアミド化合物
BRPI1014322A2 (pt) * 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
EP2635124A4 (en) * 2010-11-01 2014-04-16 Romark Lab Lc ALKYLSULFINYL-SUBSTITUTED THIAZOLIDE COMPOUNDS
CA2836253C (en) * 2011-05-16 2021-02-16 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
AU2016201747B2 (en) * 2011-05-16 2017-06-01 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
WO2015000431A1 (zh) * 2013-07-04 2015-01-08 中国人民解放军军事医学科学院毒物药物研究所 替唑尼特氨基甲酸酯及其在药学中的应用
CN104771398B (zh) * 2014-01-09 2017-01-18 湖南大学 N‑[5‑（2‑硝基乙基）噻唑‑2‑基]苯甲酰胺及其医药用途
BR112017009651A2 (pt) 2014-11-11 2017-12-19 Romark Laboratories Lc composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
EP3677282A1 (en) 2016-03-31 2020-07-08 Romark Laboratories, L.C. Thiazolide compounds for treating viral infections
HUE060671T2 (hu) 2016-04-11 2023-04-28 Genfit Eljárás fibrotikus betegségek kezelésére
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
CN107286149B (zh) * 2017-05-10 2021-02-12 南华大学 N-(5-胡椒基噻唑-2-基)哌啶基酰胺及其应用
CN107235927B (zh) * 2017-06-22 2019-04-16 湖南大学 N-(5-酰基噻唑-2-基)哌嗪基酰胺及其医药用途
CN107141267B (zh) * 2017-06-22 2019-04-09 湖南大学 N-(5-酰基噻唑-2-基)酰胺及其制备方法与应用
KR102077833B1 (ko) * 2018-12-10 2020-02-14 류형준 기능성 식품조성물
US20220193021A1 (en) * 2019-05-03 2022-06-23 President And Fellows Of Harvard College Combination therapy for treating influenza virus infection
JP7320402B2 (ja) 2019-08-08 2023-08-03 ローム株式会社 Ｍｅｍｓセンサ
WO2021046446A1 (en) * 2019-09-06 2021-03-11 Yourchoice Therapeutics, Inc. Compositions and methods of use for enhancing fertility
CN112480104B (zh) * 2019-09-11 2024-06-18 绍兴君科臻元医药科技有限公司 硝唑尼特衍生物及其医药用途
CN111743899B (zh) * 2020-01-21 2021-03-30 中国人民解放军军事科学院军事医学研究院 硝唑尼特及其活性形式替唑尼特在制备用于治疗SARS-CoV-2感染的药物中的应用
WO2021180251A1 (zh) * 2020-03-09 2021-09-16 北京强新生物科技有限公司 治疗冠状病毒感染的联用药物及治疗方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
RU2726070C1 (ru) * 2020-03-23 2020-07-08 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ патогенетической коррекции метаболических нарушений при инфекционном мононуклеозе, вызванном вирусом Эпштейна-Барр
WO2021202600A1 (en) * 2020-03-30 2021-10-07 The Scripps Research Institute Small molecule inhibitors of influenza hemagglutinin
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
CN116367892A (zh) 2020-08-24 2023-06-30 罗马克实验室有限公司 噻唑化物抗冠状病毒的用途
US20240002332A1 (en) * 2020-11-18 2024-01-04 Wenwei HUANG Small Molecule Inhibitors of SARS-CoV-2 Infections
WO2022206084A1 (zh) * 2021-03-29 2022-10-06 北京大学 噻唑类化合物在制备治疗和预防癌症药物中的用途
WO2022214855A1 (es) * 2021-04-10 2022-10-13 Siegfried Rhein, S.A. De C.V. Uso de nitazoxanida para la preparación de medicamento para prevenir o tratar infección causada por coronavirus sars-cov-2
CN115197164A (zh) * 2021-04-12 2022-10-18 杜心赟 新型噻唑类化合物及其制备方法和用途
CN113277994A (zh) * 2021-05-18 2021-08-20 杜心赟 噻唑类化合物及其制备方法和用途
WO2023198095A1 (zh) * 2022-04-12 2023-10-19 成都贝诺科成生物科技有限公司 一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1177206A (en) 1967-11-28 1970-01-07 Pfizer & Co C Lung Antiviral Factor
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4343945A (en) 1979-01-23 1982-08-10 Olin Corporation 5-Benzamido-3-trichloromethyl-1,2,4-thiadiazoles and their use as herbicides, fungicides and insecticides
US4337081A (en) 1979-01-23 1982-06-29 Olin Corporation 5-Amido-3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides
SU910628A1 (ru) 1980-04-22 1982-03-07 Гродненский государственный медицинский институт Способ получени 2-ациламинотиазолов
JPS56158703A (en) 1980-05-10 1981-12-07 Sankyo Co Ltd Fungicide
US4416683A (en) 1980-09-16 1983-11-22 Eli Lilly And Company Benzamides, compositions and agricultural method
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US5169846A (en) 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
ATE267798T1 (de) 1994-01-28 2004-06-15 Univ Kentucky Res Found Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
SI0755386T1 (en) 1994-04-13 2002-10-31 Romark Laboratories, L.C. Benzamide derivative, compositions containing said derivative and use thereof
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
CA2288003C (en) 1997-05-07 2003-10-21 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
BR9911914B1 (pt) 1998-07-08 2010-10-19 n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
CA2433018A1 (en) 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
WO2002092584A1 (fr) 2001-05-14 2002-11-21 Nihon Nohyaku Co., Ltd. Derives du thiadiazole, pesticides a usage agricole et horticole, et leurs utilisations
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003335680A (ja) 2002-05-21 2003-11-25 Otsuka Pharmaceut Factory Inc Ａｃａｔ−１阻害剤
EP1510207A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC MEDICAMENT AGAINST DIABETES
WO2004028471A2 (en) * 2002-09-28 2004-04-08 Massachusetts Institute Of Technology Influenza therapeutic
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US6737382B1 (en) 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US7432287B2 (en) 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
WO2004085433A2 (en) 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2532313A1 (en) 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Medicament for treatment of dermal pigmentation
US20050090506A1 (en) 2003-10-24 2005-04-28 Nippon Soda Co., Ltd. Insecticidal perfluoroalkylthiazole derivatives
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
UA90864C2 (xx) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Галогенізовані похідні бензаміду$галогенизированные производные бензамида
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
JP2008538362A (ja) 2005-04-12 2008-10-23 ロマーク ラボラトリーズ エル．シー． タンパク質の成熟の遮断を介して疾患を処置するための方法、タンパク質ジスルフィドイソメラーゼなどの分子シャペロンの機能を阻害する、またはグリコシル化を妨害する化合物、それらを含む薬学的組成物、および治療剤を同定するためのスクリーニング方法
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
ES2525217T3 (es) 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
RU2008107868A (ru) 2005-08-02 2009-09-10 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназ
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
WO2007125103A2 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
AU2007266535A1 (en) 2006-05-31 2007-12-06 Abbott Laboratories Thiazole compounds as cannabinoid receptor ligands and uses thereof
CA2654898A1 (en) 2006-07-07 2008-10-01 Boehringer Ingelheim International Gmbh New chemical compounds
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
JP2010511728A (ja) 2006-12-05 2010-04-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｉｌ−８受容体アンタゴニスト
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
BRPI0815057B8 (pt) 2007-08-03 2021-05-25 Romark Laboratories Lc composto, composição farmacêutica, e, uso de um composto
WO2009065096A1 (en) 2007-11-16 2009-05-22 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
MX2011005233A (es) 2008-11-19 2011-06-01 Schering Corp Inhibidores de diacilglicerol aciltransferasa.
EP2408770B1 (en) 2009-03-20 2014-11-05 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
JP5918124B2 (ja) 2009-05-12 2016-05-18 ロマーク ラボラトリーズ エル．シー． ハロアルキルヘテロアリールベンズアミド化合物
BRPI1014322A2 (pt) * 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.

Also Published As

Publication number Publication date
EP2445349B1 (en) 2022-02-09
US10363243B2 (en) 2019-07-30
US20100330173A1 (en) 2010-12-30
CA2766642A1 (en) 2010-12-29
AU2010264479A1 (en) 2012-01-19
US9345690B2 (en) 2016-05-24
US20180078533A1 (en) 2018-03-22
JP5932640B2 (ja) 2016-06-08
KR20170141830A (ko) 2017-12-26
KR101812054B1 (ko) 2017-12-27
ZA201200263B (en) 2012-09-26
ES2914949T3 (es) 2022-06-17
CA2968113C (en) 2019-05-14
EA030679B1 (ru) 2018-09-28
US20150250768A1 (en) 2015-09-10
EA201270077A1 (ru) 2012-12-28
KR20180032689A (ko) 2018-03-30
US9820975B2 (en) 2017-11-21
AU2017221828A1 (en) 2017-09-21
MX2012000230A (es) 2012-01-25
BR122020003634B1 (pt) 2021-03-16
US10912768B2 (en) 2021-02-09
CN108042535A (zh) 2018-05-18
MX341877B (es) 2016-09-06
JP6188863B2 (ja) 2017-08-30
PT2445349T (pt) 2022-05-16
BR122020003634B8 (pt) 2021-07-27
US11850237B2 (en) 2023-12-26
JP2012531420A (ja) 2012-12-10
KR20190120436A (ko) 2019-10-23
CA3038405A1 (en) 2010-12-29
HK1255283A1 (zh) 2019-08-09
US20190307730A1 (en) 2019-10-10
JP6464225B2 (ja) 2019-02-06
CA2766642C (en) 2017-09-05
CA2968113A1 (en) 2010-12-29
CA3038405C (en) 2022-02-01
EP3895706A1 (en) 2021-10-20
US9023877B2 (en) 2015-05-05
EP2445349A4 (en) 2012-12-05
US20160228415A1 (en) 2016-08-11
JP2017197552A (ja) 2017-11-02
JP2016172749A (ja) 2016-09-29
WO2010151577A1 (en) 2010-12-29
KR20120102570A (ko) 2012-09-18
CN102480967A (zh) 2012-05-30
EP2445349A1 (en) 2012-05-02
US20210177809A1 (en) 2021-06-17
BRPI1014322A2 (pt) 2015-08-25
AU2010264479B2 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
HK1255283A1 (zh) 用於治療流感的化合物和方法
HK1247820A1 (zh) 預防或治療代謝綜合症的方法
IL212348A0 (en) Treatment method
HK1167618A1 (zh) 消毒方法
IL213619A0 (en) Treatment
WO2011005473A9 (en) Methods for treating or preventing fatigue
GB0802116D0 (en) Treatment
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
GB0822011D0 (en) Treatment
EP2391391A4 (en) STERILIZATION PROCESS
IL217492A0 (en) Treatment method
EP2405946A4 (en) STERILIZATION PROCESS
GB0811992D0 (en) Treatment
GB0900599D0 (en) Treatment
GB0802201D0 (en) Treatment system
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
GB0820972D0 (en) Treatment
AP2012006279A0 (en) Method for treating waste.
IL218120A0 (en) Sterilization method
GB0823273D0 (en) Treatment system
GB0907249D0 (en) New process and new compounds
GB0805912D0 (en) Treatment
IL216957A0 (en) Exo-s-mecamylamine method, use, and compound for treatment
GB0914373D0 (en) Treatment method